Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1964

1.

Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.

Rutter JL, Smith AM, Dávila MR, Sigurdson AJ, Giusti RM, Pineda MA, Doody MM, Tucker MA, Greene MH, Zhang J, Struewing JP.

Hum Mutat. 2003 Aug;22(2):121-8.

PMID:
12872252
2.

Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.

Cao AY, Huang J, Hu Z, Li WF, Ma ZL, Tang LL, Zhang B, Su FX, Zhou J, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Yuan WT, Shen ZZ, Huang W, Shao ZM.

Breast Cancer Res Treat. 2009 May;115(1):51-5. doi: 10.1007/s10549-008-0052-z.

PMID:
18483852
3.

Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.

Guénard F, Labrie Y, Ouellette G, Joly Beauparlant C, Simard J, Durocher F; INHERIT BRCAs..

J Hum Genet. 2008;53(7):579-91. doi: 10.1007/s10038-008-0285-z.

PMID:
18414782
5.

Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.

Patmasiriwat P, Bhothisuwan K, Sinilnikova OM, Chopin S, Methakijvaroon S, Badzioch M, Padungsutt P, Vattanaviboon P, Vattanasapt V, Szabo C, Saunders GF, Goldgar D, Lenoir GM.

Hum Mutat. 2002 Sep;20(3):230.

PMID:
12203997
6.

Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer.

Lewis AG, Flanagan J, Marsh A, Pupo GM, Mann G, Spurdle AB, Lindeman GJ, Visvader JE, Brown MA, Chenevix-Trench G; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer..

Breast Cancer Res. 2005;7(6):R1005-16.

7.

Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.

Manguoglu AE, Lüleci G, Ozçelik T, Colak T, Schayek H, Akaydin M, Friedman E.

Hum Mutat. 2003 Apr;21(4):444-5.

PMID:
12655560
8.

Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.

Shiri-Sverdlov R, Oefner P, Green L, Baruch RG, Wagner T, Kruglikova A, Haitchick S, Hofstra RM, Papa MZ, Mulder I, Rizel S, Bar Sade RB, Dagan E, Abdeen Z, Goldman B, Friedman E.

Hum Mutat. 2000 Dec;16(6):491-501.

PMID:
11102978
9.

Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.

Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, Kainu T, Syrjäkoski K, Pyrhönen S, Kallioniemi OP, Muhonen T, Luce M, Frank TS, Nevanlinna H.

Hum Mol Genet. 1997 Dec;6(13):2309-15.

PMID:
9361038
10.

Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families.

Osorio A, Barroso A, Martínez B, Cebrián A, San Román JM, Lobo F, Robledo M, Benítez J.

Br J Cancer. 2000 Apr;82(7):1266-70.

11.

Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer.

Struewing JP, Brody LC, Erdos MR, Kase RG, Giambarresi TR, Smith SA, Collins FS, Tucker MA.

Am J Hum Genet. 1995 Jul;57(1):1-7.

12.

BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families.

Sarantaus L, Auranen A, Nevanlinna H.

Int J Oncol. 2001 Apr;18(4):831-5.

PMID:
11251181
13.

BACH1 Ser919Pro variant and breast cancer risk.

Vahteristo P, Yliannala K, Tamminen A, Eerola H, Blomqvist C, Nevanlinna H.

BMC Cancer. 2006 Jan 24;6:19.

14.

Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families.

Krajc M, Teugels E, Zgajnar J, Goelen G, Besic N, Novakovic S, Hocevar M, De Grève J.

BMC Med Genet. 2008 Sep 10;9:83. doi: 10.1186/1471-2350-9-83.

15.

Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414del4 found in male breast cancer.

Balci A, Huusko P, Pääkkönen K, Launonen V, Uner A, Ekmekçi A, Winqvist R.

Eur J Cancer. 1999 May;35(5):707-10.

PMID:
10505028
16.

Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.

Giannini G, Capalbo C, Ristori E, Ricevuto E, Sidoni T, Buffone A, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A.

Breast Cancer Res Treat. 2006 Nov;100(1):83-91.

PMID:
16847550
17.

BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families.

Peixoto A, Salgueiro N, Santos C, Varzim G, Rocha P, Soares MJ, Pereira D, Rodrigues H, Bento MJ, Fráguas A, Moura G, Regateiro F, Castedo S, Teixeira MR.

Fam Cancer. 2006;5(4):379-87.

PMID:
16826315
18.

BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.

Yazici H, Bitisik O, Akisik E, Cabioglu N, Saip P, Muslumanoglu M, Glendon G, Bengisu E, Ozbilen S, Dincer M, Turkmen S, Andrulis IL, Dalay N, Ozcelik H.

Br J Cancer. 2000 Sep;83(6):737-42.

19.

Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.

Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DE, Provencher D, Ghadirian P, Narod SA.

Am J Hum Genet. 1998 Nov;63(5):1341-51.

20.

BCoR-L1 variation and breast cancer.

Lose F, Arnold J, Young DB, Brown CJ, Mann GJ, Pupo GM; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer., Khanna KK, Chenevix-Trench G, Spurdle AB.

Breast Cancer Res. 2007;9(4):R54. Erratum in: Breast Cancer Res. 2008;10(5):406.

Supplemental Content

Support Center